Founded in 2005, Biodesix discovers and commercializes cancer tests (diagnostics) that help patients and their doctors make more informed decisions about treatment based on a patient’s unique molecular profile. We’re advancing precision medicine by helping oncologists provide the right patient with the right treatment at the right time.
Unlike most cancer diagnostics, our tests require only a blood draw (instead of a biopsy, where a sample of the tumor is removed from a patient’s body) and results are available within 72 hours. Biodesix collaborates with leading researchers and builds strategic partnerships with biotechnology and pharmaceutical companies to develop companion diagnostics and build our pipeline of new products.
Biodesix’ research and development activities are conducted with the highest clinical integrity, including external validation with medical experts and properly designed and controlled clinical trials. Our internal controls are designed to ensure compliance with applicable federal, state, and local statutes and regulations relevant to providers of healthcare services.